Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease

Mostrar otras versiones (1)

Repurposing FDA-approved inhibitors able to prevent infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could provide a rapid path to establish new therapeutic options to mitigate the effects of coronavirus disease 2019 (COVID-19). Proteolytic cleavages of the spike S protein o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreutzberger, Alex J.B., Sanyal, Anwesha, Ojha, Ravi, Pyle, Jesse D., Vapalahti, Olli, Balistreri, Giuseppe, Kirchhausen, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183009/
https://www.ncbi.nlm.nih.gov/pubmed/34100014
http://dx.doi.org/10.1101/2021.06.01.446623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183009/
https://www.ncbi.nlm.nih.gov/pubmed/34100014
http://dx.doi.org/10.1101/2021.06.01.446623

Ejemplares similares